EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN ...Middle East

STOCKHOLM, Feb. 20, 2025 /PRNewswire/ -- Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) and primary immune complex...

Read More Details
Finally We wish PressBee provided you with enough information of ( EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN )

Also on site :

• Disturbed’s David Draiman Met with Some Boos at Final Black Sabbath Concert
• Man shot dead outside North Oakland home
• Police investigation underway on Boardman Street near Monroe Avenue